• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Senseonics Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    5/16/25 5:20:57 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care
    Get the next $SENS alert in real time by email
    false 0001616543 0001616543 2025-05-15 2025-05-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d) OF THE

    SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of earliest event reported): May 15, 2025

     

    SENSEONICS HOLDINGS, INC.
    (Exact Name of Registrant as Specified in its Charter)

     

    Delaware   001-37717   47-1210911
    (State or Other
    Jurisdiction of Incorporation)
      (Commission File Number)   (IRS Employer
    Identification No.)

     

    20451 Seneca Meadows Parkway
    Germantown, MD 20876-7005
    (Address of Principal Executive Office) (Zip Code)

     

    Registrant's telephone number, including area code: (301) 515-7260

     

    Not Applicable

    Former name or former address, if changed since last report

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

     

    ¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class Trading Symbol(s) Name of each exchange on which registered
    Common Stock SENS NYSE American

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

     

    Item 1.01 Entry into a Material Definitive Agreement.

     

    On May 15, 2025, Senseonics Holdings, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with TD Securities (USA) LLC and Barclays Capital Inc., as representatives of the several underwriters named therein (collectively, the “Underwriters”), pursuant to which the Company agreed to issue and sell an aggregate of 100,000,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”) at a price to the public of $0.50 per share. Under the terms of the Underwriting Agreement, the Company also granted the Underwriters an option, exercisable for 30 days, to purchase up to an additional 15,000,000 shares of Common Stock.

     

    The net proceeds to the Company from the offering are expected to be approximately $45,400,000, after deducting the underwriting discounts and commissions and estimated offering expenses payable by the Company, or $52,450,000 if the Underwriters exercise in full their option to purchase 15,000,000 additional shares. All of the Shares are being sold by the Company. The closing of the offering is expected to occur on May 19, 2025, subject to the satisfaction of customary closing conditions.

     

    The securities described above are offered and will be issued pursuant to an effective shelf registration statement on Form S-3 (File No. 333-273882) and the related prospectus and prospectus supplement.

      

    The Underwriting Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriters, including for liabilities under the Securities Act of 1933, as amended (the “Securities Act”), other obligations of the parties and termination provisions. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement, and may be subject to limitations agreed upon by such parties.

     

    The foregoing descriptions of the terms of the Underwriting Agreement do not purport to be complete and are qualified in their entirety by reference to the Underwriting Agreement, which is filed as Exhibit 1.1 hereto, and is incorporated herein by reference. A copy of the opinion of Cooley LLP relating to the legality of the issuance and sale of the securities in the offering is filed as Exhibit 5.1 hereto. 

     

     

     

    Item 7.01 Regulation FD Disclosure.

     

    On May 15, 2025, the Company issued a press release announcing that the Company had commenced the offering and on May 15, 2025, the Company issued a press release announcing that it had priced the offering. Copies of these press releases are attached hereto as Exhibits 99.1 and 99.2 hereto, respectively.

     

    The information furnished with this Item 7.01 of this Current Report on Form 8-K and Exhibits 99.1 and 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act or the Exchange Act.

     

    Forward-Looking Statements

     

    This Current Report on Form 8-K contains forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward-looking statements include all statements that do not relate solely to historical or current facts, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. These forward-looking statements include statements about the offering, such as the expected net proceeds and anticipated closing date. These forward-looking statements are based on information currently available to the Company and its current plans or expectations, and are subject to a number of uncertainties and risks that could significantly affect current plans. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including the uncertainties related to market conditions and the completion of the offering on the anticipated terms or at all. The Company’s forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning the Company’s business are described in additional detail in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (“SEC”) on March 3, 2025, Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 8, 2025, and other filings the Company makes with the SEC from time to time . The Company is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit No.   Description
    1.1   Underwriting Agreement, dated May 15, 2025, by and among Senseonics Holdings, Inc., TD Securities (USA) LLC and Barclays Capital Inc.
    5.1   Opinion of Cooley LLP
    23.1   Consent of Cooley LLP (included in Exhibit 5.1)
    99.1   Press Release, dated May 15, 2025
    99.2   Press Release, dated May 15, 2025
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      Senseonics Holdings, Inc.
         
    Date: May 16, 2025 By: /s/ Rick Sullivan
       

    Rick Sullivan

    Chief Financial Officer

     

     

     

    Get the next $SENS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SENS

    DatePrice TargetRatingAnalyst
    10/21/2025$9.00Hold
    Stifel
    8/27/2025$1.50Overweight
    Barclays
    7/15/2025$1.25Buy
    TD Cowen
    6/2/2025$1.10Buy
    H.C. Wainwright
    4/10/2025$2.00Outperform
    Mizuho
    7/19/2023$0.50Underperform
    Jefferies
    8/19/2021$6.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $SENS
    SEC Filings

    View All

    SEC Form 10-K filed by Senseonics Holdings Inc.

    10-K - Senseonics Holdings, Inc. (0001616543) (Filer)

    3/2/26 4:37:33 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    Senseonics Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Senseonics Holdings, Inc. (0001616543) (Filer)

    3/2/26 4:32:07 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    Senseonics Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

    8-K - Senseonics Holdings, Inc. (0001616543) (Filer)

    1/12/26 8:25:36 AM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    $SENS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Steven Edelman bought $65,500 worth of shares (10,000 units at $6.55), increasing direct ownership by 15% to 74,708 units (SEC Form 4)

    4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

    11/13/25 4:48:53 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Sullivan Frederick T. bought $31,840 worth of shares (5,415 units at $5.88), increasing direct ownership by 4% to 157,028 units (SEC Form 4)

    4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

    11/10/25 7:40:12 AM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    Director Roeder Douglas A bought $87,450 worth of shares (15,000 units at $5.83), increasing direct ownership by 18% to 99,727 units (SEC Form 4)

    4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

    11/10/25 7:40:13 AM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    $SENS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Fiorentino Edward was granted 2,398 shares, increasing direct ownership by 3% to 71,363 units (SEC Form 4)

    4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

    1/5/26 5:45:06 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    Director Roeder Douglas A was granted 2,504 shares, increasing direct ownership by 3% to 102,231 units (SEC Form 4)

    4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

    1/5/26 5:45:10 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    Director Prince Douglas S was granted 1,379 shares, increasing direct ownership by 2% to 56,743 units (SEC Form 4)

    4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

    1/5/26 5:45:11 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    $SENS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $SENS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

    Generated Q4 revenue of $14.3 million, an increase of 72% year-over-year Received CE Mark approval for commercialization of Eversense 365 in Europe Launched first Eversense 365 AID system integration, with twiist in the US GERMANTOWN, Md., March 02, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS) a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced fourth quarter 2025 financial results and provided a business update. Recent Highlights & Accomplishments Generated fourth quarter 2025 revenue of $14.3 million, an increase

    3/2/26 4:01:00 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    Sequel Med Tech and Senseonics Launch Transformative Combination of twiist™ and Eversense® 365

    MANCHESTER, N.H. and GERMANTOWN, Md., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Sequel Med Tech, LLC, a company developing transformative drug delivery technologies, and Senseonics Holdings, Inc. (NASDAQ:SENS), a medical technology company focused on long-term, implantable Continuous Glucose Monitoring (CGM) systems for people with diabetes, today announced full availability of the twiist™ Automated Insulin Delivery (AID) System integrated with the Eversense® 365 CGM system across the U.S. Powered by Tidepool, twiist is the first AID system compatible with Eversense 365, the world's only one-year CGM. This powerful combination is a significant leap forward for the diabetes community, offering a t

    2/19/26 8:00:00 AM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    Senseonics Receives European Approval for Eversense 365, World's Longest-lasting Continuous Glucose Monitor

    GERMANTOWN, Md., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced CE Mark approval for the Eversense® 365 CGM system. Eversense 365 is the world's first and only one year CGM, which was approved by the United States (US) Food and Drug Administration in September of 2024 and launched across the country in October of the same year. The Eversense 365 CE Mark submission was prepared in compliance with the EU Medical Device Regulation (MDR) and is now approved for commercialization in 

    1/29/26 4:01:00 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    Stifel resumed coverage on Senseonics with a new price target

    Stifel resumed coverage of Senseonics with a rating of Hold and set a new price target of $9.00

    10/21/25 7:22:14 AM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    Barclays initiated coverage on Senseonics with a new price target

    Barclays initiated coverage of Senseonics with a rating of Overweight and set a new price target of $1.50

    8/27/25 8:26:33 AM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    TD Cowen initiated coverage on Senseonics with a new price target

    TD Cowen initiated coverage of Senseonics with a rating of Buy and set a new price target of $1.25

    7/15/25 8:44:36 AM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    $SENS
    Financials

    Live finance-specific insights

    View All

    Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

    Generated Q4 revenue of $14.3 million, an increase of 72% year-over-year Received CE Mark approval for commercialization of Eversense 365 in Europe Launched first Eversense 365 AID system integration, with twiist in the US GERMANTOWN, Md., March 02, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS) a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced fourth quarter 2025 financial results and provided a business update. Recent Highlights & Accomplishments Generated fourth quarter 2025 revenue of $14.3 million, an increase

    3/2/26 4:01:00 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    Senseonics Announces Preliminary Unaudited Revenue for Fourth Quarter 2025 and Provides Business Update

    Preliminary unaudited revenue expected to be approximately $14.2 million for Q4 2025, an increase of 71% year-over-year Introduced 2026 revenue guidance of $58-$62 million Expects to report fourth quarter and full year 2025 financial results on March 2, 2026 GERMANTOWN, Md., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced preliminary revenue for the fourth quarter of 2025 and provided a general business update. Recent Highlights & Accomplishments Generated preliminary unaudite

    1/12/26 8:00:00 AM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    Senseonics Holdings, Inc. Reports Third Quarter Financial Results

    Generated Q3 revenue of $8.1 million, representing year-over-year growth of 90% Achieved a 160% increase in U.S. new patient starts over prior year Planning for the transition of CGM commercial responsibility from Ascensia Diabetes Care back to Senseonics GERMANTOWN, Md., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the third quarter ended September 30, 2025. Recent Highlights & Accomplishments: Generated revenue of $8.1 million in the third quarter of 2

    11/5/25 4:05:00 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    $SENS
    Leadership Updates

    Live Leadership Updates

    View All

    Vistagen Appoints Nick Tressler as Chief Financial Officer

    Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Nick Tressler as Chief Financial Officer (CFO), effective today, December 1, 2025. "I am excited to welcome Nick to Vistagen as our CFO. His financial and strategic acumen and extensive operational experience in the biopharmaceutical industry will be instrumental as we accelerate into our next phase," said President and Chief Executive Officer of Vistagen, Shawn Singh. "I look forward to his contributions to our leadership team and the po

    12/1/25 8:30:00 AM ET
    $AZN
    $SENS
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    $SENS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Senseonics Holdings Inc. (Amendment)

    SC 13G/A - Senseonics Holdings, Inc. (0001616543) (Subject)

    2/13/24 5:13:59 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Senseonics Holdings Inc. (Amendment)

    SC 13G/A - Senseonics Holdings, Inc. (0001616543) (Subject)

    7/7/23 4:35:55 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Senseonics Holdings Inc.

    SC 13G - Senseonics Holdings, Inc. (0001616543) (Subject)

    4/10/23 5:10:45 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care